QS Investors’s Epizyme, Inc EPZM Stock Holding History

QS Investors’s Portfolio EPZM Stock Details EPZM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q3	–	Sell	-82,496	Closed	-$1.12M	–	1957
2018 Q2	$1.12M	Hold	82,496	–	–	0.01%	755
2018 Q1	$1.46M	Sell	82,496 -5,306	-6%	-$89.6K	0.02%	677
2017 Q4	$1.1M	Sell	87,802 -4,866	-5%	-$70.7K	0.01%	779
2017 Q3	$1.76M	Sell	92,668 -1,858	-2%	-$28.3K	0.01%	649
2017 Q2	$1.43M	Hold	94,526	–	–	0.01%	683
2017 Q1	$1.62M	Hold	94,526	–	–	0.01%	661
2016 Q4	$1.14M	Hold	94,526	–	–	0.01%	731
2016 Q3	$930K	Hold	94,526	–	–	0.01%	787
2016 Q2	$968K	Hold	94,526	–	–	0.01%	775
2016 Q1	$1.15M	Hold	94,526	–	–	0.01%	743
2015 Q4	$1.51M	Hold	94,526	–	–	0.01%	716
2015 Q3	$1.22M	Hold	94,526	–	–	0.01%	731
2015 Q2	$2.27M	Hold	94,526	–	–	0.03%	584
2015 Q1	$1.78M	Hold	94,526	–	–	0.02%	621
2014 Q4	$1.78M	Buy	+94,526	New	+$2.21M	0.02%	609

Other funds holding EPZM

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

VOYA Investment Management Atlanta, Georgia $116B AUM 61.47% 1-Year Est. Return

QS Investors's EPZM Position: Q3 2018 in Review

QS Investors sold out of Epizyme, Inc (EPZM) in Q3 2018, closing a stake of 82,496 shares — an estimated $1.12M sold.

QS Investors first reported a position in EPZM in Q4 2014 and held it in 15 quarters. The position peaked at $2.27M in Q2 2015. 104 funds tracked by Wall St. Rank hold EPZM as of Q3 2018.

QS Investors reported no remaining Epizyme, Inc position as of Q3 2018 after selling out during the quarter.
QS Investors sold 82,496 Epizyme, Inc shares in Q3 2018, an estimated $1.12M.
QS Investors first reported a position in Epizyme, Inc in Q4 2014 and held it in 15 quarters.
QS Investors's Epizyme, Inc position peaked at $2.27M in Q2 2015.
104 funds tracked by Wall St. Rank held Epizyme, Inc as of Q3 2018.

Based on QS Investors's 13F filing for Q3 2018, filed 14 Nov 2018.